Thu, Mar 13, 2014, 6:03 PM EDT - U.S. Markets closed  Immune
Pharmaceuticals, Inc. Message Board    • morons_finder
morons_finder Feb 5, 2008 6:47 PM Flag      Here I go again
The crown jewel in EPCT is their Apoptosis screening technology.
Every major company has their eye on this company. Question is,
when will jack throw in the towel. I have a feeling the reason
MYGN is not talking about Azixa is because this is a whole new
class of drugs and they are worried about a bigger player
getting involved in the game!      SortNewest  |  Oldest  | 
Most Replied Expand all replies     • As a matter of fact EPCT's
anti-cancer screening apoptosis platform ASAP represents an own
and significant value. This kind of discovery technologies
belongs to the most valuable assets of a pharma company. Such
platforms speed up development and can reduce the expensive risk
of needless clinical trials. "Big pharma" already made many
attempts, also paid big money, to get involved or to acquire
such kind techniques, however, "b